CORRESPONDENCE

Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19

To the Editor:

In the clinical course of COVID-19, the disease is primarily driven by the replication of SARS-CoV-2 and subsequently includes a dysregulated inflammatory response to the virus leading to tissue damage, thrombosis, and other life-threatening complications. In chronic myeloproliferative neoplasms (MPN) including essential thrombocythemia (ET), polycythemia vera (PV), prefibrotic myelofibrosis (pre-PMF), and overt myelofibrosis (MF) an excess of deaths was seen during the first wave, particularly in MF. The pandemic original wave, sustained by the wild type virus, substantially subsided in Europe until October 2020 but new viral variants of concern (VOCs) emerged thereafter, raising new difficulties of management of these vulnerable unvaccinated patients. Emergency departments were overwhelmed by the epidemic and confronted both with highly suspected SARS-CoV-2 infection patients and with early or advanced documented disease. This made difficult to assess factors associated with a rapid progression into a life-threatening severe disease particularly in patients with MPN, many of whom were in need of cytoreductive or antithrombotic therapy.

With the aim to investigate determinants of hospitalization and severity of COVID-19 and to explore whether MPN patients could have specific risks of critical illness, we examined a large cohort of 479 patients with MPN diagnosed in several European countries during the first and second wave of the pandemic. Patients were included in the MPN-COVID study (ClinicalTrials.gov identifier: NCT04385160), promoted by European LeukemiaNet (ELN) and the Foundation for Research (FROM) at Papa Giovanni XXIII Hospital in Bergamo.

Continuous variables were summarized with median along with interquartile range (IQR), and categorical ones were presented as frequencies and percentages. Characteristics of the study population were stratified for hospitalization and differences between the two groups tested with the χ² test (or Fisher's exact test where appropriate) or rank-sum test for categorical or continuous variables, respectively. Frequency distributions and Kernel density functions were calculated for COVID-19 incidence across time by patient's disposition. Receiver Operating Characteristic (ROC) curves for the prediction of hospitalization were used to compare different blood count measures and the Liu's method to find the best cut-off. A logistic Generalized Additive Model (GAM) was fitted to test parameters continuous trend prediction for the risk of hospitalization.

Using a multivariable logistic regression model, association with hospitalization was evaluated for the following variables: age, sex, presence of at least one comorbidity, MPN type, previous thrombosis, ruxolitinib exposure, COVID-19 main symptoms (fever, dyspnea, systemic), O₂ saturation, and neutrophils-to-lymphocytes ratio (NLR). Onset of dyspnea was ascertained by the physician and often associated with cough and precipitous drops in oxygen saturation. Marginal prediction probabilities of hospitalization were calculated in a final logistic model that included statistically significant factors only and their terms of interaction.

COHORT CHARACTERISTICS AND UNIVARIATE ANALYSIS

The enrolled and analyzed patients encompassed ET (n = 175), PV (n = 158), MF (n = 91), and pre-PMF (n = 55). Based on each individual single center physician’s decision, 248 and 231 were managed at home or hospitalized, respectively. Note in the Figure S1 the difference in the frequency and density of hospitalization in the first wave compared to the following one up to June 2021.

Differences between non-hospitalized and hospitalized patients are summarized in Table S1. Compared to outpatients, those admitted to hospital were more likely to be men (58.9% vs. 45.2%, p = .003), older than 70 years (61.3% vs. 29.0%, p < .001), with at least one comorbidity (79.7% vs. 55.5%, p < .001), and history of thrombosis (26.5% vs. 16.6%, p = .008). MF cases were more frequently hospitalized rather than PV, ET, or pre-PMF (38.5% vs. 18.1%, p < .001) as well as the proportion of patients on ruxolitinib was higher in hospital than at home (25.7% vs. 12.1%, p < .001).
Marginal probability of hospitalization according to age, NLR and dyspnea. NLR, neutrophil-to-lymphocyte ratio. Marginal probability of hospitalization across different patient’s ages calculated from the logistic model that included age, NLR and dyspnea and their terms of interaction.

Other differences between the two groups concerned the greater frequency in hospitalized patients of lower values of hemoglobin (12.1 vs. 13.3 g/dL, p < .001), platelet number (250 vs. 390 × 10^9/L, p < .001), absolute lymphocyte count (0.8 vs. 1.4 × 10^9/L, p < .001) and higher neutrophil counts (5.1 vs. 4.5 × 10^9/L, p = 0.022), leading to a significant higher levels of NLR inflammatory biomarker (6.6 vs. 3.2, p < .001).

Among blood count measures, the best sensitivity and specificity values predicting for hospitalization were found for NLR, particularly compared with lymphopenia alone (Figure S2a): AUC was 77.28% by ROC analysis, with the optimal cut-off of 4, and log transformed Odds Ratios (logORs) for hospitalization by GAM logistic regression analysis was almost linear (Figure S2b).

PREDICTORS OF HOSPITALIZATION

In multivariate analysis, adjusting for sex, comorbidity, fever, systemic symptoms, O2 saturation, previous thrombosis, MPN type, and ruxolitinib exposure, three factors emerged as independent predictors of hospitalization: age over 70 years, (OR = 2.91, p = .037), dyspnea (OR = 7.13, p < .001) and NLR ≥4, (OR = 7.04, p < .001).

Of note, percentages of patients with these factors (i.e., age ≥ 70, dyspnea, NLR ≥4) in the first original wave (February–June 2020) was 55%, 56%, and 66%, respectively; while in the subsequent waves (until June 2021), the same frequencies declined substantially (p < .001), albeit to a lesser extent for NLR (p = .015) (Figure S3). Nevertheless, the same three factors had a similar frequency during the first and second wave analyzed separately in outpatients and in the hospitalized ones. The only exception was for dyspnea, present in a lower percentage of outpatients in the second than in first wave.

The marginal effect of NLR and dyspnea was evaluated across different age classes in a model fitted to test the interaction terms of the three significant variables (Figure 1). In younger patients (i.e., from 50 to 70 years) dyspnea was the stronger predictor than increased NLR; conversely, dyspnea and NLR both showed a high and comparable marginal effect in age > 80 years. Remarkably, the probability of hospitalization consistently exceeded 90% for any age group when dyspnea and NLR were concomitantly present, and their combination was more prevalent in MF (42%) than in the other diseases (24%, 25%, and 29% in pre-PMF, PV and ET patients, respectively). In addition to predict hospitalization, dyspnea and NLR≥4 were also associated with severity of COVID-19 illness, based on the need of respiratory support (OR = 2.44, p = .023).

Our results indicate that in patients with MPN at COVID-19 diagnosis, the concomitant presence of dyspnea and elevated NLR inflammatory biomarker identified a subgroup of patients at a higher risk for hospitalization. Moreover, we showed that the onset of early dyspnea was also a factor to predict the worsening of respiratory function in these hospitalized patients.

In non MPN population, age and comorbidities were found powerful predictors of requirement for admission to hospital rather than outpatient care; however, degree of oxygen impairment and markers of inflammation were most strongly associated with poor outcomes during hospital admission. Accordingly, it was suggested that clinicians should consider routinely obtaining inflammatory markers during hospital stay for people with COVID-19. We highlight here that inflammatory biomarkers should be determined at the very beginning onset of coronavirus infection just after the diagnosis of COVID-19 since these MPN could benefit of a prompt therapy.

Notably, the combination of dyspnea and elevated NLR levels was prevalent in MF patients rather than in PV, ET, or pre-PMF and had an independent prognostic value at any age. This is not surprising given that among the classic MPNs, a systemic and latent inflammatory status is intrinsically more pronounced in MF than in other MPNs and the SARS-CoV-19 may exacerbate the deleterious clinical effect consequent to hyperinflammation status. It follows that the presence of elevated levels of NLR as a consequence of the marked reduction of lymphocyte counts and neutrophilia, should be considered a warning signal for a prompt therapy-decision making with anti-inflammatory and anti-viral therapy, particularly in the presence of symptoms. Non-steroidal-anti-inflammatory-drugs (NSAIDs) have been recently suggested for the management of outpatients with early symptoms of COVID-19 to mitigate hospitalization and infection severity. However, whether NSAIDs can provide a favorable risk–benefit profile in all MPN patients has not yet been explored and caution should be exerted in MPN patients who are constitutively prone to bleeding tendency.

FUNDING INFORMATION

The study was supported by a research grant by the COVID “3 × 1 project”, BREMBO S.p.A., Bergamo, Italy (T.B.) and by AIRC 5 × 1000 caLL “Metastatic disease: the key unmet need in oncology” to MYNERVA project. #21267 (MYeoloid NEoplasms Research Venture AIRC). A detailed description of the MYNERVA project is available at https://progettomynerva.it (A.M.V., P.G.). The study was also
supported by HARMONY PLUS, which is funded through the Innovative Medicines Initiative (IMI), Europe’s largest public–private initiative aiming to speed up the development of better and safer medicines for patients. The HARMONY Alliance has received funding from IMI 2 Joint Undertaking and is listed under grant agreement No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.

CONFLICT OF INTEREST
None of the authors have any conflicts of interest or financial ties to disclose in connection with the current paper.

DATA AVAILABILITY STATEMENT
Aggregated data available by request. Patient-level data will not be shared.

Tiziano Barbuli, Alessandra Carobbio, Arianna Ghirardi, Alessandra Iurlo, Marta Anna Sobas, Elena Maria Elli, Elisa Rumi, Valerio De Stefano, Francesca Lunghi, Monia Marchetti, Rosa Daffini, Mercedes Gasior Kabat, Beatriz Cuevas, Maria Laura Fox, Marcio Miguel Andrade-Campos, Francesca Palandrini, Paola Guglielmelli, Giulia Benevolo, Claire Harrison, Maria-Angeles Foncillas, Massimiliano Bonifacio, Alberto Alvarez-Larran, Jean-Jacques Kiladjian, Estefania Bolaños Calderón, Andrea Patriarca, Keina Quiroz Cervantes, Martin Griesshammer, Valentin Garcia-Gutierrez, Alberto Marin Sanchez, Elena Magro Mazo, Giuseppe Cari, Juan Carlos Hernandez-Boluda, Santiago Osorio, Gonzalez Carreno-Tarragona, Miguel Sagues Serrano, Rajko Kusec, Begona Navas Elorza, Anna Angona, Blanca Xicoy Cirici, Emma Lopez Abadía, Steffen Koschmieder, Daniele Cattaneo, Cristina Bucelli, Edyta Cichocka, Anna Kulikowska de Nałęcz, Fabrizio Cavalca, Oscar Borsani, Silvia Betti, Marta Bellini, Natalia Curto-Garcia, Alessandro Rambaldi, Alessandro Vannucchi.

1FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy
2Hematology Division, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
3Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland
4Hematology Division and Bone Marrow Transplant Unit, San Gerardo Hospital, ASST Monza, Monza, Italy
5Department of molecular medicine, University of Pavia, Pavia, Italy
6Diagnostic Imaging, Oncological Radiotherapy, and Hematology Department, Fondazione Universitaria Policlinico A. Gemelli - IRCCS - Catholic University of Sacred Heart of Rome, Rome, Italy
7Hematology and BMT Unit, University Vita-Salute San Raffaele, San Raffaele Scientific Institute, Milan, Italy
8Division of Hematology, AOU SS. Antonio e Biagio e C. Arrigo, Alessandria, Italy
9Division of Hematology, ASST-Spedali Civili, Brescia, Italy
10Division of Hematology, Hospital Universitario La Paz, Madrid, Spain
11Division of Hematology, Hospital Universitario de Burgos, Burgos, Spain
12Department of Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
13Division of Hematology, Hospital del Mar, Barcelona, Spain
14Institute of Hematology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
15Center Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy
16Hematology Unit, AOU Città della Salute e della Scienza, Turin, Italy
17Department of Haematology, Guy’s and St. Thomas’ NHS Foundation Trust, London, UK
18Hematology Unit, Hospital Universitario Infantia Leonor, Madrid, Spain
19Department of Medicine, Section of Hematology, University of Verona, Verona, Italy
20Division of Hematology, Hospital Clinic de Barcelona, Barcelona, Spain
21Centre d’Investigations Cliniques, Hospital Saint-Louis, Paris, France
22Division of Hematology, Hospital Clinic San Carlos, Madrid, Spain
23Division of Hematology, Department of Translational Medicine, AOU Maggiore della Carità, Novara, Italy
24Division of Hematology, Hospital Universitario de Mostoles, Madrid, Spain
25University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center, Minden, Germany
26Division of Hematology, Hospital Ramon y Cajal, IRYCIS, Madrid, Spain
27Division of Hematology, Hospital General Universitario de Albacete, Albacete, Spain
28Division of Hematology, Hospital Universitario Principe de Asturias, Alcalá de Henares (Madrid), Spain
29Division of Hematology, Ospedale San Bortolo, Vicenza, Italy
30Division of hematology, Hospital Clinico Universitario, INCLIVA, Valencia, Spain
31Division of Hematology, Hospital Gregorio Maranon, Madrid, Spain
32Division of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain
33Division of Hematology, ICO L’Hospitalet-Hospital Moises Broggi, Sant Joan Despí (Barcelona), Spain
34Department of haematology, Clinic of internal medicine, University Hospital Dubrava-School of Medicine University of Zagreb, Zagreb, Croatia
References

1. Barbui T, Vannucchi AM, Alvarez-Larran A, et al. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia. 2021;35(2):485-493.

2. Barbui T, Iurlo A, Masciulli A, et al. Second versus first wave of COVID-19 in patients with MPN. Leukemia. 2022;36(3):897-900.

3. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966.

4. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29(10):1356-1363.

5. Perico N, Cortinovis M, Suter F, Remuzzi G. Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents. Lancet Infect Dis. 2022;22(2):433-439. doi:10.1016/S1473-3099(22)00433-9

Supporting Information

Additional supporting information can be found online in the Supporting Information section at the end of this article.